WHEN TO CONSIDER XCOPRI

Are your patients still experiencing seizures? It may be time to consider XCOPRI

XCOPRI^® (CENOBAMATE TABLETS) CV IS INDICATED FOR THE TREATMENT
OF PARTIAL-ONSET SEIZURES IN ADULT PATIENTS¹

XCOPRI received FDA-approval in 2020¹

0 prescriptions have been written to date for XCOPRI²*

ZERO

As many as 1 in 5 patients experienced
ZERO seizures during the maintenance
phase when taking XCOPRI^1,3,4

See XCOPRI clinical data
on ZERO seizures

XCOPRI can be prescribed
as monotherapy
or adjunctive therapy¹

Flexible, once-daily dosing to take patients through their treatment journey¹

*Total US prescriptions as of January 2022. Source: IQVIA.

References: 1. XCOPRI [package insert]. Paramus, NJ: SK Life Science, Inc. 2. Data on file, IQVIA. SK Life Science, Inc. 3. Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311-e2322. 4. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients
with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):28-48.

MOA

XCOPRI is thought to work via a multimodal mechanism of action¹*

XCOPRI has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents, including inhibiting the component of the sodium current¹

XCOPRI Reducing Repetitive Neuronal Firing by Inhibiting Voltage-Gated Sodium Currents Model

XCOPRI is also a positive allosteric modulator of the y-aminobutyric acid (GABA_A) ion channel¹

XCOPRI Positive Allosteric Modulator of Y-Aminobutyric Acid (GABAA) Ion Channel Model

XCOPRI IN ACTION

See how flexible, once-daily XCOPRI dosing can work for your patients¹

*The precise mechanism by which XCOPRI exerts its anticonvulsant activity is unknown.¹

Reference: 1. XCOPRI [package insert]. Paramus, NJ: SK Life Science, Inc.

INDICATION

XCOPRI^® (cenobamate tablets) CV is indicated for the treatment of partial-onset seizures in adult patients.

Important Safety Information
and indication

CONTRAINDICATIONS
XCOPRI^® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

For US Healthcare Professionals Only

For US Healthcare Professionals Only

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI^® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI^® is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.

XCOPRI is contraindicated in patients with Familial Short QT syndrome.

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end‑stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

Please see Full Prescribing Information.